For analytical instruments in this AI era, the mantra is: Throughput. Throughput. Throughput.
Too often, solubility & aggregation work still means slow handoffs, compound-hungry methods, and an analytical queue that delays decisions later in the process. The bottleneck has never been the science. It has been the workflow design.
The ORYL F1 workflow demo shows what a different approach looks like — plate-based from acquisition to output, results within one hour from plate prep to report. This is why we call it Solubility & Aggregation Profiling That Keeps Pace with Modern Drug Discovery.
Plate to report, no queue in between
Plate preparation takes minutes. Compounds go into a standard 384-well plate at ~2 µL of 10 mM DMSO per datapoint — no columns to pack, no mobile phases, no overnight equilibration. The plate goes straight into ORYL F1. Acquisition runs through ORYL Screener: a full 384-well plate in ~15 minutes, with 50 ms integration and 10 acquisitions per well, capturing SHS and LLS simultaneously in each well. Sensitivity is below 1 µM.
Data review happens in ORYL Analyzer. Outliers are flagged automatically, replicates aggregated, and the software produces decision-ready output: LLS-derived (or SHS-derived) solubility profiles, solubility limits with confidence intervals, and concentration-response curves. PDF reports and CSV exports in a single click. No post-processing pipeline. No manual data handling.
And the impressive part about it, is that the analyzer can handle batch processing of plates, 100+ compounds done in seconds.
Why getting there fast changes the decision
A workflow that delivers results in under an hour can run on discovery timelines. The shortlist is still forming. The chemistry isn’t yet in flight. Physical-property data at this stage changes which compounds get promoted — and which problems get caught before they travel downstream.
A workflow that delivers results days later arrives when the shortlist is already set. It can flag problems, but it can’t change the initial decision. The pipeline has already committed. That’s the difference the demo makes visible.
What changes at the handoff
Discovery scientists get solubility and aggregation data while they’re still triaging. Pre-formulation teams inherit a data trail instead of starting from scratch. The compounds that reach development are the ones that can actually survive it.
Profiling that keeps pace with modern drug discovery.
It is called F1 for a reason.